AmoyDx® Essential NGS panel approval from Chinese authority
Time:2018-11-21Source : AmoyDx

AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer (CRC). It is the first Companion Diagnostic (CDx) NGS kit approved in China covering different cancer types.

AmoyDx® Essential NGS panel is a library preparation kit based on Illumina platform, involved EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes which are mostly recommended for mutation detection by the guidelines for NSCLC and CRC. Among the 10 genes, EGFR mutation testing was approved as CDx solution with Gefitinib & Osimertinib, ALK and ROS1 fusion testing were approved as CDx with Crizotinib on NSCLC, and KRAS mutation testing was approved as CDx with Cetuximab on CRC. 
With the innovative patented ddCapture® technology, AmoyDx® Essential NGS panel has Limit of Detection (LOD) of 1%. While according to the validation data on Horizon® standard DNA, the mutations can be well detected on 0.5% allele frequency.
AmoyDx is the market leader in China providing cancer gene mutations testing kits to over 300 top-tier hospitals. Essential NGS panel is the first AmoyDx® NGS product approved by Chinese NMPA. AmoyDx product lines cover different technical platforms including qPCR, FISH and NGS, providing the most comprehensive solutions on cancer mutation testing for precision oncology in China and overseas.

For more information, please call us at +86-592-6806835 or email us at sales@amoydx.com.



Tel:+86-592-6806835
Email:sales@amoydx.com
BACK
Recommend
Visit AmoyDx at European Lung Cancer Congress 2019 in Geneva
27 /03
Visit AmoyDx at AACR Annual Meeting 2019 in Atlanta, USA
26 /03
AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit approved by Chinese Authority
01 /03
Welcome to visit AmoyDx on 17th Congress on Targeted Anticancer Therapies (TAT) in Paris
26 /02
Sanomics Limited and Amoy Diagnostics Partner to Deliver Multi-Gene Tests in Hong Kong and Macau
28 /01
AmoyDx ROS1 Kit Approval in Taiwan
18 /12
AmoyDx® Essential NGS panel approval from Chinese authority
21 /11
2018 AmoyDx Distributors Annual Meeting successfully held in Shanghai
11 /11
Visit AmoyDx at AMP Annual Meeting 2018 in USA
02 /11
AmoyDx ROS1 Gene Fusions Detection Kit was Approved by South Korea MFDS as Companion Diagnostics for Pfizer's Crizotinib
10 /10
Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada
21 /09
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
24 /08
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
04 /04
China NMPA grants approval to AmoyDx Super-ARMS EGFR mutation test kit
22 /01
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017
05 /12
AmoyDx Distributors Annual Meeting (Europe) 2017
20 /11
Visit AmoyDx at MEDICA 2017, Germany
17 /11
Visit AmoyDx at MEDICA 2017 in Germany
20 /10
Amoy Diagnostics exhibits in the18th World Conference on Lung Cancer(WCLC) in Yokohama, Japan
20 /10
Detection sensitivity or therapeutic response prediction accuracy, which weighs more on NSCLC EGFR blood testing?
20 /09
Visit AmoyDx at WCLC 2017 of IASLC in Japan
16 /08
Amoy Diagnostics Co., Ltd. achieved IPO on Shenzhen Stock Exchange
02 /08
AmoyDx attended News Conference of Xalkori ROS1 approval in Japan
28 /06
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
22 /05
AmoyDx in European Lung Cancer Conference (ELCC) 2017
09 /05
Visit AmoyDx at ELCC 2017 in Switzerland
21 /04
AmoyDx HER2 Mutation Test Acting as Companion Diagnostics for Boehringer Ingelheim's Afatinib Study in NSCLC Patients
14 /02
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
03 /02
TOP
Inquiry
* Required information
Manage your account info
Change your password